Leerink Partners Upgrades Biogen (BIIB) to Outperform

November 7, 2016 10:33 AM EST
Get Alerts BIIB Hot Sheet
Price: $283.58 -0.01%

Rating Summary:
    18 Buy, 16 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 22 | Down: 32 | New: 34
Trade BIIB Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Leerink Partners upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $365.00.

Analyst Geoffrey Porges commented, "This morning Biogen announced positive interim data for CHERISH, a phase III study of Spinraza (nusinersen) for the treatment of later-onset (Type II) spinal muscular atrophy (SMA). The positive outcome of this trial did not come as a surprise to us given our recent research with MEDACorp KOLs in the field of SMA, but the timing was certainly much earlier than the company’s guidance and than our expectations. The timing and result materially increases the assurance that the initial label for nusinersen will include all, or at least most forms of SMA and thus gives the drug even more near term revenue potential than we have modeled previously."

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $277.00 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Upgrades

Add Your Comment